Lane-level opportunity view across countries and weekly pulses, backed by published signals and evidence lockers.
Clinical data shows Eli Lilly's tirzepatide causes significant lean muscle loss compared to semaglutide. This creates a massive secondary market for 'muscle-sparing' supplements and protocols for the millions on GLP-1s.
The FDA is eyeing the expansion of testosterone therapy specifically for libido. This moves TRT from 'clinical deficiency' to 'lifestyle enhancement,' drastically lowering customer acquisition costs.
The FDA is reclassifying 12 unapproved peptides, potentially moving them into the legal compounding pharmacy lane. This signals a regulatory truce that could 10x the legal biohacking market.
Eli Lilly's oral GLP-1 (Foundayo) is clearing safety hurdles. This signals the end of the 'cold chain' logistics nightmare and the beginning of mass-market oral adoption.